Drugs | Qatar Business Standard

Dr. Falk Pharma and Allianthera (Suzhou) Biopharmaceuticals Forge Strategic Partnership for Novel AhR Agonist Development

on July 30, 2025

Freiburg (Germany), Suzhou (China) and Boston (USA), July 30, 2025:

Dr. Falk Pharma GmbH and Allianthera (Suzhou) Biopharmaceuticals Co., Ltd. Announce Strategic Partnership to Develop a Novel AhR Agonist for the [...] Read more »

Dr. Falk Pharma und Allianthera (Suzhou) Biopharmaceuticals gehen strategische Partnerschaft für die Entwicklung eines neuartigen AhR-Agonisten ein

on July 30, 2025

Freiburg (Deutschland), Suzhou (China) und Boston (USA), 30. Juli 2025:

Dr. Falk Pharma GmbH und Allianthera (Suzhou) Biopharmaceuticals Co., Ltd. geben strategische Partnerschaft für die Entwicklung eines [...] Read more »

Dr. Falk Pharma gibt positive Ergebnisse seiner zulassungs-relevanten Phase-III-Studie zu Norucholsäure bei primär sklerosierender Cholangitis bekannt

on May 7, 2025

Freiburg, den 7. Mai 2025

Die Studienergebnisse zeigen die Überlegenheit von Norucholsäure (NCA) gegenüber Placebo im kombinierten primären Endpunkt. Es gibt derzeit kein zugelassenes [...] Read more »

Dr. Falk Pharma announces positive results from its pivotal phase 3 trial on norucholic acid in primary sclerosing cholangitis

on May 7, 2025

Freiburg, May 7^th, 2025

Study results demonstrate superiority of norucholic acid (NCA) over placebo in the combined primary endpoint. There is currently no approved medicine to treat [...] Read more »

DEBRICHEM® Wins 2025 IIWCG Achievement Award for Innovation in Wound Care

on April 30, 2025

AMSTERDAM, April 30, 2025 (GLOBE NEWSWIRE) — DEBRICHEM®, the flagship product of DEBx Medical has been awarded the IIWCG Achievement Award 2025 for Innovation in Wound Care at the [...] Read more »

DEBRICHEM® se voit décerner le prix 2025 IIWCG Achievement Award récompensant l’innovation dans le domaine du soin des plaies

on April 30, 2025

AMSTERDAM, 30 avr. 2025 (GLOBE NEWSWIRE) — DEBRICHEM®, le produit phare de DEBx Medical, a obtenu le prix IIWCG Achievement Award 2025 récompensant l’innovation dans le [...] Read more »

Curium schließt Übernahme von Monrol im Rahmen seines Plans zur erheblichen Ausweitung der Lutetium-177-Kapazitäten und der Präsenz im Bereich der Positronen-Emissions-Tomographie (PET) ab

on March 28, 2025

Dies positioniert Curium als führenden Hersteller des Isotops Lu–177
Integration innovativer [...] Read more »

Curium Finaliza a Aquisição da Monrol como Parte do seu Plano para Expandir Significativamente a Capacidade de Lutécio-177 e Pegada PET

on March 28, 2025

Aquisição posiciona a Curium como principal fabricante do isótopo Lu–177
Oferece experiência [...] Read more »

Curium finalise l’acquisition de Monrol, axée sur le net renforcement de sa capacité de production de lutécium-177 et de son empreinte PET

on March 28, 2025

Affirmation de son leadership dans la production de l’isotope lutétium–177
Renforcement de son expertise [...] Read more »

Curium Completes the Acquisition of Monrol as Part of its Plan to Significantly Expand Lutetium-177 Capacity and PET Footprint

on March 28, 2025

Positions Curium as leading manufacturer of Lu–177 isotope
Brings innovative R&D expertise and pipeline to Curium
Enhances Curium’s SPECT & PET geographical [...] Read more »

DEBx Medical Secures Expanded Investment from TVM Capital Healthcare

on November 13, 2024

DEBx Medical is poised for accelerated growth in chronic wound solutions, bolstered by the second round of investment by TVM Capital Healthcare.

AMSTERDAM and DUBAI, United Arab Emirates, Nov. 13, 2024 [...] Read more »

A DEBx Medical garante investimento expandido da TVM Capital Healthcare

on November 13, 2024

A DEBx Medical está preparada para um crescimento acelerado em soluções para feridas crônicas, com o apoio da segunda rodada de investimento da TVM Capital Healthcare.

AMSTERDÃ e DUBAI, [...] Read more »

DEBx Medical obtient de nouveaux investissements auprès de TVM Capital Healthcare

on November 13, 2024

Grâce au deuxième tour d’investissement de TVM Capital Healthcare, DEBx Medical s’apprête à accélérer sa croissance dans le domaine des solutions de traitement des plaies [...] Read more »

M	T	W	T	F	S	S
« Dec
			1	2	3	4
5	6	7	8	9	10	11
12	13	14	15	16	17	18
19	20	21	22	23	24	25
26	27	28	29	30	31

Angelini Pharma Signs Exclusive Option Agreement With Sovargen To License Global Development and Commercialization Rights For Innovative Brain Health Asset

Extrovis AG and Dr. Reddy’s announce the launch of the authorized generic of CARAC (fluorouracil cream), 0.5% in the U.S.

Dr. Falk Pharma and Allianthera (Suzhou) Biopharmaceuticals Forge Strategic Partnership for Novel AhR Agonist Development

Dr. Falk Pharma und Allianthera (Suzhou) Biopharmaceuticals gehen strategische Partnerschaft für die Entwicklung eines neuartigen AhR-Agonisten ein

Dr. Falk Pharma gibt positive Ergebnisse seiner zulassungs-relevanten Phase-III-Studie zu Norucholsäure bei primär sklerosierender Cholangitis bekannt

Dr. Falk Pharma announces positive results from its pivotal phase 3 trial on norucholic acid in primary sclerosing cholangitis

DEBRICHEM® Wins 2025 IIWCG Achievement Award for Innovation in Wound Care

DEBRICHEM® se voit décerner le prix 2025 IIWCG Achievement Award récompensant l’innovation dans le domaine du soin des plaies

Curium schließt Übernahme von Monrol im Rahmen seines Plans zur erheblichen Ausweitung der Lutetium-177-Kapazitäten und der Präsenz im Bereich der Positronen-Emissions-Tomographie (PET) ab

Curium Finaliza a Aquisição da Monrol como Parte do seu Plano para Expandir Significativamente a Capacidade de Lutécio-177 e Pegada PET

Curium finalise l’acquisition de Monrol, axée sur le net renforcement de sa capacité de production de lutécium-177 et de son empreinte PET

Curium Completes the Acquisition of Monrol as Part of its Plan to Significantly Expand Lutetium-177 Capacity and PET Footprint

DEBx Medical Secures Expanded Investment from TVM Capital Healthcare

A DEBx Medical garante investimento expandido da TVM Capital Healthcare

DEBx Medical obtient de nouveaux investissements auprès de TVM Capital Healthcare